Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery.

[1]  P. Kesharwani,et al.  Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers , 2015, Drug development and industrial pharmacy.

[2]  Yi Jin,et al.  Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery , 2015, Drug development and industrial pharmacy.

[3]  Yanyan Jiang,et al.  Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release , 2015, Drug delivery.

[4]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[5]  S. Kannan,et al.  Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications , 2014, Journal of internal medicine.

[6]  N. K. Jain,et al.  Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. , 2014, Nanomedicine.

[7]  T. Higashi,et al.  Preparation and evaluation of polyamidoamine dendrimer conjugate with glucuronylglucosyl-β-cyclodextrin (G3) as a novel carrier for siRNA , 2014, Journal of drug targeting.

[8]  Chao Chen,et al.  Targeted delivery of Dicer-substrate siRNAs using a dual targeting peptide decorated dendrimer delivery system. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[9]  Tamer Refaat,et al.  Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. , 2014, Molecular and clinical oncology.

[10]  Mingwu Shen,et al.  Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer. , 2014, ACS applied materials & interfaces.

[11]  Deep Pooja,et al.  Dendrimer-TPGS mixed micelles for enhanced solubility and cellular toxicity of taxanes. , 2014, Colloids and surfaces. B, Biointerfaces.

[12]  T. Niidome,et al.  Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine) , 2014, Journal of biomaterials science. Polymer edition.

[13]  X. Li,et al.  PEGylated PAMAM dendrimer-doxorubicin conjugate-hybridized gold nanorod for combined photothermal-chemotherapy. , 2014, Biomaterials.

[14]  Keerti Jain,et al.  Dendronized nanoconjugates of lysine and folate for treatment of cancer. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  J. Kleeff,et al.  Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  N. K. Jain,et al.  Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. , 2014, Biomaterials.

[17]  Jing Zhao,et al.  Cell‐Penetrable Lysine Dendrimers for Anti‐Cancer Drug Delivery: Synthesis and Preliminary Biological Evaluation , 2014, Archiv der Pharmazie.

[18]  Yu Wang,et al.  Fluorinated poly(propylenimine) dendrimers as gene vectors. , 2014, Biomaterials.

[19]  Vladimir P Torchilin,et al.  Barriers to drug delivery in solid tumors , 2014, Tissue barriers.

[20]  C. Tros de Ilarduya,et al.  Efficient targeted gene delivery by a novel PAMAM/DNA dendriplex coated with hyaluronic acid. , 2014, Nanomedicine.

[21]  D. Owen,et al.  Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Z. Duan,et al.  Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors. , 2014, Molecular pharmaceutics.

[23]  Keerti Jain,et al.  Dendrimer as nanocarrier for drug delivery , 2014 .

[24]  P. Sætrom,et al.  Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo , 2014, Hepatology.

[25]  S. Ganta,et al.  Role of integrated cancer nanomedicine in overcoming drug resistance. , 2013, Advanced drug delivery reviews.

[26]  H. Gérard,et al.  Dendrimer-enabled DNA delivery and transformation of Chlamydia pneumoniae. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[27]  T. Minko,et al.  Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug , 2013, Clinical Cancer Research.

[28]  D. Ma,et al.  Photoenhanced gene transfection by a star-shaped polymer consisting of a porphyrin core and poly(L-lysine) dendron arms. , 2013, Macromolecular bioscience.

[29]  Jian-tao Lin,et al.  New cyclodextrin derivative containing poly(L-lysine) dendrons for gene and drug co-delivery. , 2013, Journal of colloid and interface science.

[30]  Dzmitry G. Shcharbin,et al.  Nanomaterials in stroke treatment: perspectives. , 2013, Stroke.

[31]  R. Tekade,et al.  Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone. , 2013, Current drug delivery.

[32]  Jintian Tang,et al.  Pharmaceutical nanotechnology for oral delivery of anticancer drugs. , 2013, Advanced drug delivery reviews.

[33]  Scott H. Medina,et al.  Enzyme-activated nanoconjugates for tunable release of doxorubicin in hepatic cancer cells. , 2013, Biomaterials.

[34]  R. Tekade,et al.  The effect of polyethylene glycol spacer chain length on the tumor-targeting potential of folate-modified PPI dendrimers , 2013, Journal of Nanoparticle Research.

[35]  M. Zloh,et al.  Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo. , 2013, ACS nano.

[36]  Michael Riediker,et al.  Therapeutic nanoparticles in clinics and under clinical evaluation. , 2013, Nanomedicine.

[37]  J. Hsieh,et al.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. , 2013, Molecular pharmaceutics.

[38]  Kui Luo,et al.  Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. , 2013, Biomaterials.

[39]  R. Dinarvand,et al.  A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis , 2013, Cancer Chemotherapy and Pharmacology.

[40]  Jianru Xiao,et al.  Reducing cytotoxicity while improving anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation. , 2012, Acta biomaterialia.

[41]  N. K. Jain,et al.  Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates , 2012, Journal of drug targeting.

[42]  Prashant Kesharwani,et al.  Carbon nanotube exploration in cancer cell lines. , 2012, Drug discovery today.

[43]  N. K. Jain,et al.  Spectrophotometric estimation of paclitaxel , 2011 .

[44]  N. K. Jain,et al.  The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates. , 2011, Biomaterials.

[45]  L. Kaminskas,et al.  Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. , 2011, Nanomedicine.

[46]  Mansoor Amiji,et al.  Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery. , 2011, Accounts of chemical research.

[47]  N. K. Jain,et al.  Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[48]  Anupama Sharma,et al.  Surface modified dendrimers: synthesis and characterization for cancer targeted drug delivery. , 2011, Bioorganic & medicinal chemistry.

[49]  Jian-ping Xu,et al.  Polyamidoamine dendrimers surface-engineered with biomimetic phosphorylcholine as potential drug delivery carriers. , 2011, Colloids and surfaces. B, Biointerfaces.

[50]  Thommey P. Thomas,et al.  Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agent. , 2011, Bioorganic & medicinal chemistry.

[51]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[52]  Min Zhang,et al.  Multifunctional Triblock Nanocarrier (PAMAM-PEG-PLL) for the Efficient Intracellular siRNA Delivery and Gene Silencing , 2011, ACS nano.

[53]  S. Valiyaveettil,et al.  Active targeting of cancer cells using folic acid-conjugated platinum nanoparticles. , 2010, Nanoscale.

[54]  G. Drossopoulou,et al.  Synthesis of a folate functionalized PEGylated poly(propylene imine) dendrimer as prospective targeted drug delivery system. , 2010, Bioorganic & medicinal chemistry letters.

[55]  W. A. Yeudall,et al.  Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery. , 2010, Oral oncology.

[56]  R. Konwar,et al.  Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. , 2010, International journal of pharmaceutics.

[57]  T. Minko,et al.  Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[58]  B. Nanjwade,et al.  Dendrimers: emerging polymers for drug-delivery systems. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[59]  N. K. Jain,et al.  Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent. , 2009, Biomaterials.

[60]  N. K. Jain,et al.  Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics , 2009, Journal of microencapsulation.

[61]  Narendra Kumar Jain,et al.  Dendrimers in oncology: an expanding horizon. , 2009, Chemical reviews.

[62]  T. Xu,et al.  Targeting cancer cells with biotin-dendrimer conjugates. , 2009, European journal of medicinal chemistry.

[63]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[64]  M. Ogris,et al.  Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[65]  Dong-Eun Kim,et al.  Evaluation of generations 2, 3 and 4 arginine modified PAMAM dendrimers for gene delivery. , 2008, International journal of pharmaceutics.

[66]  S. Betigeri,et al.  Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. , 2008, Bioconjugate chemistry.

[67]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[68]  Michihiro Nakamura,et al.  Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles , 2007, International journal of cancer.

[69]  P. Erba,et al.  Towards the use of nanoparticles in cancer therapy and imaging. , 2007, Drug news & perspectives.

[70]  J. Rossi,et al.  RNAi therapeutics: principles, prospects and challenges. , 2007, Advanced drug delivery reviews.

[71]  E. Simanek,et al.  Dendrimers as drug delivery vehicles: non-covalent interactions of bioactive compounds with dendrimers. , 2007, Polymer international.

[72]  D. Tomalia,et al.  Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. , 2007, Biochemical Society transactions.

[73]  T. Mandal,et al.  Engineered nanoparticles in cancer therapy. , 2007, Recent patents on drug delivery & formulation.

[74]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[75]  Shi Yunyu,et al.  Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. , 2006, European journal of medicinal chemistry.

[76]  T. Wu,et al.  Prospects of RNA interference therapy for cancer , 2006, Gene Therapy.

[77]  M. Dewhirst,et al.  Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.

[78]  R. Griffey,et al.  Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2'-O-alkyl modifications. , 2006, Journal of medicinal chemistry.

[79]  R. Duncan,et al.  Dendrimer biocompatibility and toxicity. , 2005, Advanced drug delivery reviews.

[80]  Anil K Patri,et al.  Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. , 2005, Advanced drug delivery reviews.

[81]  H. Hui,et al.  Thermo- and pH-sensitive dendrimer derivatives with a shell of poly(N,N-dimethylaminoethyl methacrylate) and study of their controlled drug release behavior , 2005 .

[82]  A. Schätzlein,et al.  Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. , 2005, Cancer research.

[83]  L. Bohm,et al.  Evaluation of cisplatin and a novel platinum polymer conjugate for drug toxicity and drug distribution in mice , 2005, Anti-cancer drugs.

[84]  D. Tomalia.  Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry , 2005 .

[85]  F. Hirayama,et al.  Enhancing effects of galactosylated dendrimer/alpha-cyclodextrin conjugates on gene transfer efficiency. , 2005, Biological & pharmaceutical bulletin.

[86]  E. W. Meijer,et al.  Multivalency in the gas phase: the study of dendritic aggregates by mass spectrometry. , 2004, Angewandte Chemie.

[87]  S. Sahoo,et al.  Nanotech approaches to drug delivery and imaging. , 2003, Drug discovery today.

[88]  Manouchehr Mirshahi,et al.  Efficacy of dendrimer‐mediated angiostatin and TIMP‐2 gene delivery on inhibition of tumor growth and angiogenesis: In vitro and in vivo studies , 2003, International journal of cancer.

[89]  S. Jain,et al.  A PEGylated dendritic nanoparticulate carrier of fluorouracil. , 2003, International journal of pharmaceutics.

[90]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[91]  Thommey P. Thomas,et al.  Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor , 2002, Pharmaceutical Research.

[92]  Takuro Niidome,et al.  In vitro gene transfection using dendritic poly(L-lysine). , 2002, Bioconjugate chemistry.

[93]  H. Maeda,et al.  Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[94]  F. Hirayama,et al.  Enhancement of gene expression by polyamidoamine dendrimer conjugates with alpha-, beta-, and gamma-cyclodextrins. , 2001, Bioconjugate chemistry.

[95]  J. Fréchet,et al.  Fast and convenient divergent synthesis of aliphatic ester dendrimers by anhydride coupling. , 2001, Journal of the American Chemical Society.

[96]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[97]  M. Rymaszewski,et al.  Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. , 2000, Human gene therapy.

[98]  M. Milella,et al.  Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. , 2000, American journal of clinical oncology.

[99]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[100]  J. Fréchet,et al.  Designing dendrimers for drug delivery. , 1999, Pharmaceutical science & technology today.

[101]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[102]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[103]  Yanan Liu,et al.  Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance. , 2015, Acta biomaterialia.

[104]  Xue Ying,et al.  PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. , 2011, Biomaterials.

[105]  Huixin He,et al.  Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. , 2011, Current drug delivery.

[106]  Robert Blumenthal,et al.  Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. , 2009, Critical reviews in therapeutic drug carrier systems.

[107]  Lee Josephson,et al.  Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. , 2009, Cancer biomarkers : section A of Disease markers.

[108]  E. Bárdi,et al.  Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer , 2008, Pathology & Oncology Research.

[109]  S. Parveen,et al.  Polymeric nanoparticles for cancer therapy. , 2008, Journal of drug targeting.

[110]  J. Fréchet,et al.  Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.

[111]  H. Maeda,et al.  Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. , 2003, Clinical pharmacokinetics.

[112]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[113]  James R. Dewald,et al.  A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .